JP2020515578A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515578A5 JP2020515578A5 JP2019553113A JP2019553113A JP2020515578A5 JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5 JP 2019553113 A JP2019553113 A JP 2019553113A JP 2019553113 A JP2019553113 A JP 2019553113A JP 2020515578 A5 JP2020515578 A5 JP 2020515578A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutically acceptable
- acceptable salt
- antibody
- drug conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *N(C(CC1)=O)C1=O Chemical compound *N(C(CC1)=O)C1=O 0.000 description 4
- XJLIZVNBNOGQIZ-UHFFFAOYSA-N CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O Chemical compound CC(C)(CCOC(C)(C)CCN(C(C=C1)=O)C1=O)C(NCCNC)=O XJLIZVNBNOGQIZ-UHFFFAOYSA-N 0.000 description 1
- QXYUPYCLYVKFML-UHFFFAOYSA-N CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O Chemical compound CC(C)NCCN(C(C(Br)=C1Br)=O)C1=O QXYUPYCLYVKFML-UHFFFAOYSA-N 0.000 description 1
- CEKBIZXSKXIHKR-QWRGUYRKSA-N CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC Chemical compound CC(C)[C@@H](C(N[C@@H](CCCNC(N)=O)C(C)=O)=O)NC CEKBIZXSKXIHKR-QWRGUYRKSA-N 0.000 description 1
- BYTQYJBXDFBAMS-UHFFFAOYSA-N CCN(C1OC1C(C)C1)C1=O Chemical compound CCN(C1OC1C(C)C1)C1=O BYTQYJBXDFBAMS-UHFFFAOYSA-N 0.000 description 1
- FEPCRJPVYFSZFH-UHFFFAOYSA-N CNCCN(C(C=C1)=O)C1=O Chemical compound CNCCN(C(C=C1)=O)C1=O FEPCRJPVYFSZFH-UHFFFAOYSA-N 0.000 description 1
- ZYPSDIUSNSIUEG-UHFFFAOYSA-N CNCCN(C(CC1=C)=O)C1=O Chemical compound CNCCN(C(CC1=C)=O)C1=O ZYPSDIUSNSIUEG-UHFFFAOYSA-N 0.000 description 1
- LDNWXFQQLQTQKU-UHFFFAOYSA-N CNCCNC(C(CC(O)=O)=C)=O Chemical compound CNCCNC(C(CC(O)=O)=C)=O LDNWXFQQLQTQKU-UHFFFAOYSA-N 0.000 description 1
- BNUHAJGCKIQFGE-UHFFFAOYSA-N COc(cc1)ccc1[N+]([O-])=O Chemical compound COc(cc1)ccc1[N+]([O-])=O BNUHAJGCKIQFGE-UHFFFAOYSA-N 0.000 description 1
- CVYZVNVPQRKDLW-UHFFFAOYSA-N COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O Chemical compound COc(ccc([N+]([O-])=O)c1)c1[N+]([O-])=O CVYZVNVPQRKDLW-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N CSc1ccccc1 Chemical compound CSc1ccccc1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17163065.0A EP3381474A1 (en) | 2017-03-27 | 2017-03-27 | Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy |
| EP17163065.0 | 2017-03-27 | ||
| PCT/EP2018/057744 WO2018178060A1 (en) | 2017-03-27 | 2018-03-27 | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020515578A JP2020515578A (ja) | 2020-05-28 |
| JP2020515578A5 true JP2020515578A5 (https=) | 2021-02-12 |
Family
ID=58448395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019553113A Pending JP2020515578A (ja) | 2017-03-27 | 2018-03-27 | Ｈｄａｃ阻害剤系抗体薬物コンジュゲート（ａｄｃ）及び治療における使用 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20210128740A1 (https=) |
| EP (2) | EP3381474A1 (https=) |
| JP (1) | JP2020515578A (https=) |
| KR (1) | KR20190126824A (https=) |
| CN (1) | CN110475572A (https=) |
| AU (1) | AU2018241840A1 (https=) |
| BR (1) | BR112019013449A2 (https=) |
| CA (1) | CA3047359A1 (https=) |
| EA (1) | EA201991985A1 (https=) |
| IL (1) | IL268821A (https=) |
| MX (1) | MX2019011492A (https=) |
| SG (2) | SG10202109654SA (https=) |
| TN (1) | TN2019000187A1 (https=) |
| UA (1) | UA125311C2 (https=) |
| WO (1) | WO2018178060A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12582719B2 (en) | 2019-02-25 | 2026-03-24 | Emory University | Chimeric compounds and methods of managing neurological disorders or conditions |
| US20220401564A1 (en) * | 2019-11-06 | 2022-12-22 | Dana-Farber Cancer Institute, Inc. | Selective histone deacetylase (hdac) degraders and methods of use thereof |
| BR112023000817A2 (pt) * | 2020-07-20 | 2023-02-07 | Jiangsu Hengrui Pharmaceuticals Co Ltd | Derivado de isoindolina contendo enxofre, e método de preparação do mesmo e uso médico do mesmo |
| CN112430229B (zh) * | 2020-11-24 | 2023-03-21 | 福建医科大学 | 一种靶向降解parp蛋白的化合物及其制备方法与应用 |
| CN113292465B (zh) * | 2021-06-17 | 2022-11-08 | 贵州医科大学 | 一种半胱氨酸衍生物及其合成方法、应用 |
| WO2023059581A1 (en) * | 2021-10-04 | 2023-04-13 | Halda Therapeutics Opco, Inc. | Heterobifunctional compounds and their use in treating disease |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| KR20250107900A (ko) * | 2022-11-25 | 2025-07-14 | 청두 칩스크린 뉴웨이 바이오사이언시스 컴퍼니 리미티드 | 링커, 링커를 함유하는 항체-약물 접합체 및 이의 제조 방법 및 응용 |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| CN116554079B (zh) * | 2023-07-11 | 2023-11-10 | 南京市鸿舜医药科技有限公司 | 一种组蛋白去乙酰化酶抑制剂及用途 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202543650A (zh) | 2024-03-08 | 2025-11-16 | 美商海爾達醫療運營公司 | 異雙官能化合物及其在治療疾病中之用途 |
| WO2025228384A1 (en) * | 2024-04-30 | 2025-11-06 | Hutchmed Limited | Antibody-drug conjugates and use thereof |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN121401440A (zh) * | 2025-10-21 | 2026-01-27 | 北京晟日昭阳生物科技有限公司 | 一种靶向治疗胰腺癌的抗体偶联物及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109045307A (zh) * | 2004-06-01 | 2018-12-21 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
| WO2007054719A2 (en) * | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| SG189817A1 (en) * | 2008-04-30 | 2013-05-31 | Immunogen Inc | Potent conjugates and hydrophilic linkers |
| GB201309807D0 (en) * | 2013-05-31 | 2013-07-17 | Pharma Mar Sau | Antibody drug conjugates |
| ES2809501T3 (es) * | 2013-07-05 | 2021-03-04 | Formation Biologics Inc | Conjugados de anticuerpo de EGFR |
| JP6685924B2 (ja) * | 2014-04-11 | 2020-04-22 | メディミューン，エルエルシー | システイン操作抗体を含むコンジュゲート化合物 |
-
2017
- 2017-03-27 EP EP17163065.0A patent/EP3381474A1/en not_active Withdrawn
-
2018
- 2018-03-27 JP JP2019553113A patent/JP2020515578A/ja active Pending
- 2018-03-27 BR BR112019013449A patent/BR112019013449A2/pt not_active IP Right Cessation
- 2018-03-27 MX MX2019011492A patent/MX2019011492A/es unknown
- 2018-03-27 SG SG10202109654S patent/SG10202109654SA/en unknown
- 2018-03-27 SG SG11201906543RA patent/SG11201906543RA/en unknown
- 2018-03-27 US US16/492,355 patent/US20210128740A1/en not_active Abandoned
- 2018-03-27 UA UAA201909898A patent/UA125311C2/uk unknown
- 2018-03-27 WO PCT/EP2018/057744 patent/WO2018178060A1/en not_active Ceased
- 2018-03-27 CN CN201880022128.4A patent/CN110475572A/zh active Pending
- 2018-03-27 EA EA201991985A patent/EA201991985A1/ru unknown
- 2018-03-27 AU AU2018241840A patent/AU2018241840A1/en not_active Abandoned
- 2018-03-27 KR KR1020197028286A patent/KR20190126824A/ko not_active Withdrawn
- 2018-03-27 CA CA3047359A patent/CA3047359A1/en active Pending
- 2018-03-27 EP EP18712246.0A patent/EP3600444A1/en not_active Withdrawn
- 2018-03-27 TN TNP/2019/000187A patent/TN2019000187A1/en unknown
-
2019
- 2019-08-21 IL IL26882119A patent/IL268821A/en unknown